Global Swab and Viral Transport Medium Market to Reach USD 2.2 Billion by 2030 on Back of COVID-19 Pandemic
|
By LabMedica International staff writers Posted on 03 Dec 2020 |

Illustration
The global swab and viral transport medium (VTM) market was valued at USD 0.9 billion in 2019 and will witness a moderate growth rate of ~3% from 2020 to 2030 to reach USD 2.2 billion by 2030, driven by the onslaught of COVID-19 and increasing R&D activities.
These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.
In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.
The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.
However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.
Related Links:
Transparency Market Research
These are the latest findings of Transparency Market Research (Albany NY, USA), a next-generation market intelligence provider.
The demand for swab and VTM has increased during the COVID-19 (coronavirus) pandemic. Since research institutes and labs have intensified their experiments for developing COVID-19 vaccines, companies in the swab and VTM market have increased their production capacities to develop products useful for viral collection, maintenance, and culture.
In terms of product, the transport medium segment accounted for a major share of the global swab and VTM market in 2019. The segment is anticipated to record a high CAGR during the forecast period, owing to rise in the need and demand for detection and prevention of the infectious diseases across the world. Geographically, North America accounted for a significant share of the global swab and VTM market in 2019. The presence of key players and growth strategies adopted by these players are the major factors driving the swab and VTM market in the region. The growth of the swab and VTM market in North America can also be attributed to rise in prevalence of infectious diseases. On the other hand, the Asia Pacific market is likely to grow at a rapid pace during the forecast period.
The COVID-19 pandemic has led to an unprecedented need of diagnostic reverse transcription-PCR (RT-PCR) testing. The ideal way for taking the specimen type is a nasopharyngeal (NP) swab, which can be easily transported to a molecular microbiology laboratory in VTM and the swabs for the further examinations. An increase in the demand for swabs and VTM owing to the COVID-19 pandemic is projected to drive the global swab and VTM market in the near future.
However, some factors are hampering the overall development of the global swab and VTM market, such as the increasing number of false negatives and re-infection of COVID-19 diagnosis. As such, healthcare professionals are facing issues to test performance and interpretation of COVID-19 testing, as the level of viral RNA in many cases is below the limit of detection. Hence, manufacturers in the swab and VTM market are following CDC guidelines to develop products that facilitate appropriate specimen collection.
Related Links:
Transparency Market Research
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI-Powered Liquid Biopsy Detects Liver Cancer Across Diverse Populations
Liver cancer remains a leading cause of cancer mortality worldwide, with incidence rising alongside the growing burden of metabolic liver disease. Early detection can substantially improve outcomes, yet... Read more
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelPartnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more








